A possible mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors (GIST) has been delineated in a new study. Chun-Meng Wang and colleagues identified novel KIT mutations ...

Figure 3: ABL kinase domain structure bound to imatinib, with locations of 13 ... with multiple kinase domain mutations in the same BCR-ABL molecule 16. Although the relapse rate in newly ...

CHICAGO -- The STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with investigator-selected tyrosine kinase inhibitors (TKIs) for patients with newly ...

Through chemical changes, the binding affinity for ABL was improved compared with imatinib, making nilotinib less susceptible to point mutations due to differential topological fit in the kinase ...